Bavisant
| Clinical data | |
|---|---|
| Other names | BEN-2001; BEN2001; JNJ-1074; JNJ1074; JNJ-31001074; JNJ31001074 |
| Routes of administration | Oral[1] |
| Drug class | Histamine H3 receptor receptor antagonist; Wakefulness-promoting agent |
| ATC code |
|
| Pharmacokinetic data | |
| Elimination half-life | 14–22 hours[2][3] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C19H27N3O2 |
| Molar mass | 329.444 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Bavisant (INN, USAN; developmental code names BEN-2001 and JNJ-31001074) is a histamine H3 receptor receptor antagonist which was under development for the treatment of narcolepsy and attention deficit hyperactivity disorder (ADHD) but was never marketed.[1][4][2][5] It is taken orally.[1][5]
The drug is potent and highly selective for the histamine H3 receptor (Ki = 5.4 nM).[2][5][3] Bavisant produces wakefulness-promoting effects in animals and humans, but can also cause insomnia.[2][5] Its elimination half-life is 14 to 22 hours while its effective half-life is 13 to 20 hours.[2][3]
Bavisant was under development by BenevolentAI and Johnson & Johnson.[1] It reached phase 2 clinical trials for both narcolepsy and ADHD prior to the discontinuation of its development in 2022.[1] The drug was not effective for the treatment of ADHD in a large clinical trial.[2][5] Besides the preceding indications, it was also studied for the treatment of alcoholism.[2][4] In 2026, bavisant was identified as a potential therapeutic agent for the treatment of multiple sclerosis.[6]
See also
- List of investigational attention deficit hyperactivity disorder drugs
- List of investigational narcolepsy and hypersomnia drugs
- Histamine H3 receptor antagonist
- Wakefulness-promoting agent
References
- ^ a b c d e "BenevolentAI/Johnson & Johnson". AdisInsight. 5 November 2023. Retrieved 21 May 2026.
- ^ a b c d e f g Sadek B, Łażewska D, Hagenow S, Kieć-Kononowicz K, Stark H (2016). "Histamine H3R Antagonists: From Scaffold Hopping to Clinical Candidates". Histamine Receptors. The Receptors. Vol. 28. Cham: Springer International Publishing. pp. 109–155. doi:10.1007/978-3-319-40308-3_5. ISBN 978-3-319-40306-9.
- ^ a b c Vaidyanathan S, Kramer M, Berwaerts J, Pandina G, Li LY (2012). "Pharmacokinetics And Safety Of Bavisant (JNJ-31001074) After Single And Multiple Doses In Healthy Subjects: 1386236". Clinical Pharmacology in Drug Development. 1 (4): 199.
- ^ a b Kuhne S, Wijtmans M, Lim HD, Leurs R, de Esch IJ (December 2011). "Several down, a few to go: histamine H3 receptor ligands making the final push towards the market?". Expert Opinion on Investigational Drugs. 20 (12): 1629–1648. doi:10.1517/13543784.2011.625010. PMID 21992603.
- ^ a b c d e Weisler RH, Pandina GJ, Daly EJ, Cooper K, Gassmann-Mayer C (May 2012). "Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder". CNS Drugs. 26 (5): 421–434. doi:10.2165/11631990-000000000-00000. PMID 22519922.
- ^ Gacem N, Bezukladova S, Windener F, Karam T, Ottoboni L, Brambilla E, et al. (January 2026). "In silico screening and preclinical validation identify bavisant as a therapeutic candidate for multiple sclerosis". Science Translational Medicine. 18 (833) eads0633. doi:10.1126/scitranslmed.ads0633. PMID 41564155.